ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003)
{{output}}
Objective: ReNeu (NCT03962543) is a pivotal, phase 2b trial evaluating efficacy and safety of mirdametinib (investigational MEK1/2 inhibitor) in adults and children (≥2y) with symptomatic inoperable NF1-PN. ... ...
